However, when TNBC cells are treated with ATO and ATRA, ATRA induces AQP9 and increases the uptake of ATO by cancer cells, while at the same time ATRA cooperatively inhibits Pin1 as well as other oncogenic pathways, such as NF-κB, β-catenin, c-Myc, Akt, and c-Jun [65]. The gene discussed is AKT1; the disease is cancer.